Maria Soler

Dr. Maria Soler serves as a Senior Researcher at the Catalan Institute of Nanoscience and Nanotechnology (ICN2), conducting pioneering work in the Nanobiosensors and Bioanalytical Applications group (NanoB2A) under the Networking Research Center of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Her expertise spans nanophotonic biosensor development for real-time, label-free detection in complex biomedical environments.

Her academic credentials include:

• PhD in Biochemistry, Molecular Biology and Biomedicine from Autonomous University of Barcelona (2015, with distinguished honors)
• Postdoctoral research at Ecole Polytechnique Federale de Lausanne (EPFL, Switzerland) for 3 years

Dr. Soler's research integrates optical biosensor development, nanoplasmonics, and surface chemistry with molecular biology to create diagnostic platforms for immunology and personalized medicine. The NanoB2A group focuses on nanoplasmonic biosensors, silicon nanophotonic systems, lab-on-a-chip integration, and surface biofunctionalization, targeting clinical diagnostics and environmental applications through interdisciplinary innovation.

Her publication trends reveal consistent advancement in label-free photonic biosensors for precision diagnostics, particularly in point-of-care testing for infectious diseases (including multiple SARS-CoV-2 applications) and cancer immunotherapy monitoring. This work bridges nanotechnology fundamentals with urgent healthcare needs, demonstrating exceptional translational potential in pandemic response and personalized treatment strategies.

Dr. Soler's contributions have been recognized through distinguished PhD honors and features in Laser Focus World, though specific awards remain unlisted in available materials. Her research has secured significant ERDF funding for laboratory enhancements within the Biodeposition and Biodetection Unit (U4 NANBIOSIS).

As leader of the NanoB2A laboratory at ICN2, she oversees cutting-edge equipment for nanobiosensor development and application, recently upgraded through European Regional Development Fund investments to advance diagnostic capabilities for complex biomedical challenges.